Acadia Pharmaceuticals Files Q1 2025 10-Q
Ticker: ACAD · Form: 10-Q · Filed: 2025-05-08T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, pharmaceuticals, financials, quarterly-report
TL;DR
Acadia Pharma's Q1 2025 10-Q is in. Check financials.
AI Summary
Acadia Pharmaceuticals Inc. filed its 10-Q for the period ending March 31, 2025. The filing details their financial performance and business operations. Key financial data and operational aspects are presented within this report.
Why It Matters
This filing provides investors and analysts with the latest financial snapshot of Acadia Pharmaceuticals, crucial for understanding the company's current health and future prospects.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Acadia faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2025-03-31 — Reporting Date (End of the first quarter of 2025)
- 2024-11-30 — Previous Fiscal Year End (Context for financial comparisons)
Key Players & Entities
- ACADIA PHARMACEUTICALS INC (company) — Filer
- 20250331 (date) — Period of Report
- 20250508 (date) — Filed as of Date
- Saniona (company) — License Agreement Partner
- Neuren Pharmaceuticals Limited (company) — License Agreement Partner
- DAYBUE (product) — Product Mentioned
- PRV (product) — Product Mentioned
FAQ
What is the reporting period for this 10-Q filing?
The Conformed Period of Report is 20250331, meaning the filing covers the period ending March 31, 2025.
Who are the key partners mentioned in relation to license agreements?
The filing mentions license agreements with Saniona and Neuren Pharmaceuticals Limited.
What products are referenced in the context of FDA approval and sales?
The filing references FDA Approval Sales of DAYBUE and Sale of PRV.
What is the company's Standard Industrial Classification?
The company's Standard Industrial Classification is Pharmaceutical Preparations [2834].
When was the corporate office space lease agreement entered into?
The corporate office space lease agreement was entered into on 2021-03-31.
From the Filing
0000950170-25-066231.txt : 20250508 0000950170-25-066231.hdr.sgml : 20250508 20250507211542 ACCESSION NUMBER: 0000950170-25-066231 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 68 CONFORMED PERIOD OF REPORT: 20250331 FILED AS OF DATE: 20250508 DATE AS OF CHANGE: 20250507 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ACADIA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001070494 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 061376651 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-50768 FILM NUMBER: 25923479 BUSINESS ADDRESS: STREET 1: 12830 EL CAMINO REAL STREET 2: SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 858-558-2871 MAIL ADDRESS: STREET 1: 12830 EL CAMINO REAL STREET 2: SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92130 10-Q 1 acad-20250331.htm 10-Q 10-Q Q1 0001070494 false --12-31 http://fasb.org/us-gaap/2024#ProductMember http://fasb.org/us-gaap/2024#ProductMember http://fasb.org/us-gaap/2024#ProductMember http://fasb.org/us-gaap/2024#ProductMember http://fasb.org/us-gaap/2024#ProductMember http://fasb.org/us-gaap/2024#ProductMember One http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent 0001070494 us-gaap:SalesMember acad:LicenseAgreementsMember acad:SanionaMember srt:MaximumMember 2024-11-30 0001070494 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2025-03-31 0001070494 acad:CorporateCreditCardProgramMember us-gaap:LetterOfCreditMember 2025-03-31 0001070494 2025-03-31 0001070494 acad:CorporateOfficeSpaceLeaseAgreementMember us-gaap:LetterOfCreditMember 2021-03-31 0001070494 acad:LicenseAgreementsMember acad:NeurenPharmaceuticalsLimitedMember acad:FDAApprovalSalesOfDAYBUEAndSaleOfPRVMember 2025-03-31 0001070494 acad:TwoThousandAndTwentyFourInducementPlanMember 2025-03-31 0001070494 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001070494 us-gaap:MoneyMarketFundsMember 2024-12-31 0001070494 us-gaap:FairValueInputsLevel1Member 2025-03-31 0001070494 us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember acad:InternalCostsMember 2025-01-01 2025-03-31 0001070494 us-gaap:MoneyMarketFundsMember 2025-03-31 0001070494 us-gaap:CommonStockMember 2025-03-31 0001070494 acad:SanDiegoMember 2023-12-31 0001070494 acad:StokeTherapeuticsIncMember 2022-01-31 0001070494 acad:LicenseAgreementsMember acad:SanionaMember srt:MaximumMember 2024-11-30 0001070494 acad:DaybueMember 2024-01-01 2024-03-31 0001070494 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-03-31 0001070494 us-gaap:USTreasuryNotesSecuritiesMember 2025-03-31 0001070494 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2024-12-31 0001070494 us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember acad:DaybueMember 2025-01-01 2025-03-31 0001070494 us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember acad:InternalCostsMember 2024-01-01 2024-03-31 0001070494 srt:MaximumMember 2025-03-31 0001070494 us-gaap:RetainedEarningsMember 2025-03-31 0001070494 us-gaap:FairValueInputsLevel1Member 2024-12-31 0001070494 us-gaap:CommonStockMember 2024-03-31 0001070494 acad:NuplazidMember 2024-01-01 2024-03-31 0001070494 acad:LicenseAgreementsMember acad:DevelopmentCommercializationAndSalesMilestonesMember acad:Nnz2591Member 2023-07-31 0001070494 acad:StokeTherapeuticsIncMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-01-31 0001070494 2024-01-01 2024-03-31 0001070494 us-gaap:CostOfSalesMember 2024-01-01 2024-03-31 0001070494 acad:LicenseAgreementsMember acad:DevelopmentCommercializationAndSalesMilestonesMember acad:SanionaMember srt:MaximumMember 2024-11-30 0001070494 2025-04-30 0001070494 acad:NeurenPharmaceuticalsLimitedMember acad:LicenseAgreementsMember 2025-01-01 2025-03-31 0001070494 acad:CorporateOfficeSpaceLeaseAgreementMember stpr:CA 2020-03-31 0001070